OSCR
Q3 2026 EPS Estimate
$0.34
Aug 5, 2026 · Reports before open
Revenue Estimate
$4.73B
FY2026E EPS$1.04
FY2027E EPS$1.45

Analyst Sentiment

Wall St. Consensus
Hold
11 analysts·Moderate coverage
52
Score
3 Buy (27%)6 Hold (55%)2 Sell (18%)
Rating Breakdown
Strong Buy
00%
Buy
327%
Hold
655%
Sell
218%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$16.00
-49.8%
Consensus
$20.00
-37.3%
Bull
$35.00
+9.7%
12-Month Target Range11 analysts
$16.00$20.00$35.00
Current $31.90Consensus
Current Price
$31.90
Above Consensus
$11.90

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+7.36%
EPS+38.70%
FY2028
Rev+11.55%
EPS+48.14%
FY2029
Rev+14.08%
EPS+22.29%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$18.53B$19.89B$22.19B$25.31B$28.23B
Low$18.34B$19.63B$22.12B$23.24B$25.92B
High$18.73B$20.16B$22.25B$26.23B$29.25B
EBITDA Avg$-1.80B$-1.93B$-2.15B$-2.46B$-2.74B
Low$-1.82B$-1.96B$-2.16B$-2.55B$-2.84B
High$-1.78B$-1.91B$-2.15B$-2.26B$-2.52B
EBIT Avg$-1.88B$-2.02B$-2.25B$-2.57B$-2.87B
Low$-1.90B$-2.05B$-2.26B$-2.66B$-2.97B
High$-1.86B$-1.99B$-2.25B$-2.36B$-2.63B
Net Income Avg$384M$546M$562M$687M$740M
Low$-210M$14M$505M$614M$661M
High$664M$690M$619M$720M$775M
EPS Avg$1.04$1.45$2.14$2.62$2.82
Low$-0.80$0.05$1.93$2.34$2.52
High$2.53$2.63$2.36$2.74$2.95
Analysts (Rev / EPS)7 / 67 / 66 / 45 / 23 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$4.65B$4.47B$5.12B$5.17B$5.07B$4.87B$5.84B$5.93B
Low$4.56B$4.25B$4.86B$4.91B$4.81B$4.63B$5.55B$5.63B
High$4.74B$4.63B$5.30B$5.35B$5.24B$5.04B$6.04B$6.13B
EBITDA Avg$-451M$-434M$-497M$-502M$-492M$-473M$-567M$-576M
Low$-460M$-449M$-514M$-519M$-509M$-490M$-587M$-596M
High$-443M$-412M$-472M$-476M$-467M$-449M$-539M$-547M
EBIT Avg$-472M$-454M$-520M$-525M$-515M$-495M$-594M$-602M
Low$-481M$-470M$-538M$-543M$-533M$-512M$-614M$-623M
High$-463M$-431M$-494M$-498M$-489M$-470M$-564M$-572M
Net Income Avg$-86M$-437M$690M$173M$-36M$-398M$719M$224M
Low$-116M$-456M$644M$161M$-38M$-416M$671M$209M
High$-53M$-408M$721M$180M$-34M$-371M$751M$234M
EPS Avg$-0.26$-1.32$2.09$0.52$-0.11$-1.21$2.18$0.68
Low$-0.35$-1.38$1.95$0.49$-0.11$-1.26$2.04$0.64
High$-0.16$-1.24$2.19$0.55$-0.10$-1.13$2.28$0.71
Analysts (Rev / EPS)5 / 62 / 42 / 22 / 22 / 22 / 21 / 31 / 3

Earnings Surprises

Recent Analyst Actions

Jun 15, 2026Raymond James
Raymond James on Court Ruling: 'This should be viewed as a positive OSCR and other ACA exchange players as this puts to bed the $5 rule'
Target:$30.00
+6.6%from $28.13
Jun 10, 2026Barclays
Barclays Upgrades Oscar Health Inc (OSCR) to Overweight, 'we see a visible path to an undemanding 13–15x P/E valuation'
Target:$35.00
+28.6%from $27.22
Jun 4, 2026Wells Fargo
Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight
Target:$20.00
-2.4%from $20.50
May 26, 2026Barclays
Oscar Health price target raised to $30 from $21 at Barclays
Target:$30.00
+38.2%from $21.70
May 7, 2026UBS
Oscar Health price target raised to $20 from $15 at UBS
Target:$20.00
+0.8%from $19.84
May 7, 2026Barclays
Oscar Health price target raised to $21 from $18 at Barclays
Target:$21.00
+5.8%from $19.84
Apr 20, 2026Jefferies
Oscar Health upgraded to Hold from Underperform at Jefferies
Target:$16.00
+1.3%from $15.79
Feb 12, 2026Raymond James
Oscar Health upgraded to Outperform from Market Perform at Raymond James
Target:$18.00
+32.4%from $13.60
Feb 11, 2026UBS
Oscar Health price target lowered to $15 from $17 at UBS
Target:$15.00
+10.7%from $13.56
Jan 9, 2026UBS
Oscar Health upgraded to Neutral from Sell at UBS
Target:$17.00
+0.6%from $16.90
Jan 5, 2026Barclays
Oscar Health upgraded to Equal Weight from Underweight at Barclays
Target:$18.00
+20.2%from $14.97
Oct 14, 2025Goldman Sachs
Oscar Health initiated with a Neutral at Goldman Sachs
Target:$17.00
-16.7%from $20.40
Oct 7, 2025Wells Fargo
Oscar Health price target raised to $14 from $10 at Wells Fargo
Target:$14.00
-37.2%from $22.31
Aug 14, 2025Piper Sandler
Oscar Health price target lowered to $13 from $14 at Piper Sandler
Target:$13.00
-11.2%from $14.64
Aug 8, 2024Piper Sandler
Oscar Health Inc (OSCR) PT Raised to $28 at Piper Sandler
Target:$28.00
+52.3%from $18.38
Jun 25, 2024Piper Sandler
Piper Sandler Starts Oscar Health Inc (OSCR) at Overweight
Target:$25.00
+41.7%from $17.64
Jun 12, 2024Wells Fargo
Oscar Health price target raised to $27 from $24 at Wells Fargo
Target:$27.00
+34.9%from $20.01
Jun 10, 2024Goldman Sachs
Goldman Sachs Reiterates Neutral Rating on Oscar Health Inc (OSCR)
Target:$21.00
+3.9%from $20.21
Mar 21, 2024Raymond James
Raymond James Starts Oscar Health Inc (OSCR) at Outperform
Target:$20.00
+45.3%from $13.76
Nov 15, 2022Wells Fargo
Oscar Health upgraded to Overweight from Equal Weight at Wells Fargo
Target:$4.00
+38.4%from $2.89
Nov 14, 2022Morgan Stanley
Morgan Stanley Downgrades Oscar Health to Equal-Weight, Lowers Price Target to $5
Target:$5.00
+69.5%from $2.95
Sep 1, 2022Morgan Stanley
Morgan Stanley Maintains Overweight on Oscar Health, Lowers Price Target to $9
Target:$9.00
+48.9%from $6.04
Jun 9, 2022Morgan Stanley
Morgan Stanley Maintains Overweight on Oscar Health, Lowers Price Target to $12
Target:$12.00
+129.9%from $5.22
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.